Efficacy of imiquimod in the management of lentigo maligna
Journal of the European Academy of Dermatology and Venereology · 2023-09 · 37 (9) · 1785-1791
DOI: 10.1111/jdv.19141 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.05.2023. Verfasst von Marie Daude und 19 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, INSERM, CNRS, CHU Nantes, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France. Hauptthemen laut MEDLINE: Hutchinson's Melanotic Freckle, Antineoplastic Agents, Skin Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Ministère de la Santé.
Abstract (Originalsprache)
Background
Lentigo maligna (LM) is a melanocytic proliferation occurring on photo‐exposed skin that may progress to LM melanoma. Surgery is recommended as first‐line treatment. Excision margins of 5–10 mm remain, without international consensus. Several studies have shown that imiquimod, an immunomodulator, induces LM regression. This study investigated the effect of imiquimod versus placebo in neoadjuvant settings. Patients and Methods We performed a prospective, randomized, multicentre, phase III clinical study. Patients were randomly assigned in 1:1 ratio to receive imiquimod or placebo for 4 weeks, followed by LM excision 4 weeks after the last application of imiquimod or placebo. The primary endpoint was extra‐lesional excision, with a 5 mm margin from the residual pigmentation after imiquimod or vehicle. Secondary endpoints included the gain on the surface removed between the two groups; number of revision surgeries to obtain extra‐lesional excisions; relapse‐free time; and number of complete remissions after treatment.
Results
A total of 283 patients participated in this study; 247 patients, 121 patients in the placebo group and 126 in the imiquimod group, accounted for the modified ITT population. The first extralesional extirpation was performed in 116 (92%) imiquimod patients and in 102 (84%) placebo patients; the difference was not significant ( p = 0.0743). Regarding the surface of LM, imiquimod reduced the LM surface (4.6–3.1 cm 2 ) significantly ( p < 0.001) more compared to the placebo (3.9–4.1 cm 2 ).
Conclusion
Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nantes Université, INSERM, CNRS, CHU Nantes, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France.
- Department of Dermatology, CHU Rennes, Rennes, France.
- Biostatistics and Epidemiology, Hôpital Saint Jacques - CHU Nantes, Nantes, France.
- Department of Dermatology, CH Le Mans, Le Mans, France.
- Department of Dermatology, CHU Nice, Centre de recherche Clinique, Nice, France.
- Department of Dermatology, CHU Tours, Tours, France.
ORCID-Profile: Marie Daude, Marie Beylot-Barry, Brigitte Dréno
Förderung
- Ministère de la Santé
Zitieren
APA
Daude, M., Dinulescu, M., Nguyen, J. M., Maillard, H., Le Duff, F., Machet, L., Beylot-Barry, M., Legoupil, D., Wierzbicka-Hainaut, E., Bedane, C., Leccia, M. T., Debarbieux, S., Meyer, N., Monestier, S., Bens, G., Denis, M. G., Bossard, C., Vergier, B., Khammari, A., & Dréno, B. (2023). Efficacy of imiquimod in the management of lentigo maligna. Journal of the European Academy of Dermatology and Venereology, 37(9), 1785-1791. https://doi.org/10.1111/jdv.19141
Vancouver
Daude M, Dinulescu M, Nguyen JM, Maillard H, Le Duff F, Machet L, et al. Efficacy of imiquimod in the management of lentigo maligna. Journal of the European Academy of Dermatology and Venereology. 2023;37(9):1785-1791. doi:10.1111/jdv.19141
BibTeX
@article{Daude2023,
author = {Daude, Marie and Dinulescu, Monica and Nguyen, Jean-Michel and Maillard, Hervé and Le Duff, Florence and Machet, Laurent and Beylot-Barry, Marie and Legoupil, Delphine and Wierzbicka-Hainaut, Ewa and Bedane, Christophe and Leccia, Marie Thérèse and Debarbieux, Sébastien and Meyer, Nicolas and Monestier, Sandrine and Bens, Guido and Denis, Marc G and Bossard, Celine and Vergier, Beatrice and Khammari, Amir and Dréno, Brigitte},
title = {Efficacy of imiquimod in the management of lentigo maligna},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
volume = {37},
number = {9},
pages = {1785--1791},
doi = {10.1111/jdv.19141}
}
EUVIMED